Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review

B-cell acute lymphoblastic leukemia (B-ALL) with the MLL-AF4 fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). Herein, we present a case of a 46-year-old male patient who developed relapsed B-ALL with MLL-AF4. The patient ini...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuelian Jin, Zhigang Liu, Yu Wu, Jie Ji
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
relapsed/refractory
MLL-AF4
ALL
leukemia
Bcl-2 inhibitor (venetoclax)
histone deacetylase inhibitor (chidamide)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1475974/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items